Stevanato Group S.p.A. provided earnings guidance for the year 2021. Stevanato Group continues to expand its role in the pharmaceutical value chain. The Company has established full year 2021 guidance that demonstrates a sharp focus on executing against its long-term strategic plan. The Company currently estimates that it has visibility of approximately 94% of full year forecasted revenue for fiscal 2021, comprised of first half 2021 revenue contributions plus currently estimated backlog for the second half. The Company currently expects: revenue in the range of €820 million to €830 million, which represents year-over-year growth between 24% and 25% compared to revenue of €662.0 million for fiscal year 2020, high value solutions to range between 25% and 26% of revenue for 2021.